VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo von Lee, C M, Hickey, M M, Sanford, C A, McGuire, C G, Cowey, C L, Simon, M C, Rathmell, W K

Volltext

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) von Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Rutkowski, P., Cowey, C.L., Lao, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P.F., Smylie, M., Hill, A.G., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., Wolchok, J.

Volltext

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma von Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D, Wagstaff, John, Schadendorf, Dirk, Ferrucci, Pier F, Smylie, Michael, Dummer, Reinhard, Hill, Andrew, Hogg, David, Haanen, John, Carlino, Matteo S, Bechter, Oliver, Maio, Michele, Marquez-Rodas, Ivan, Guidoboni, Massimo, McArthur, Grant, Lebbé, Celeste, Ascierto, Paolo A, Long, Georgina V, Cebon, Jonathan, Sosman, Jeffrey, Postow, Michael A, Callahan, Margaret K, Walker, Dana, Rollin, Linda, Bhore, Rafia, Hodi, F. Stephen, Larkin, James

Volltext

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma von Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C. Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier F, Smylie, Michael, Hogg, David, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bastholt, Lars, Rizzo, Jasmine I, Balogh, Agnes, Moshyk, Andriy, Hodi, F. Stephen, Wolchok, Jedd D

Volltext

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma von Weber, Jeffrey, Mandala, Mario, Del Vecchio, Michele, Gogas, Helen J, Arance, Ana M, Cowey, C. Lance, Dalle, Stéphane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus O, Middleton, Mark R, Maio, Michele, Atkinson, Victoria, Queirolo, Paola, Gonzalez, Rene, Kudchadkar, Ragini R, Smylie, Michael, Meyer, Nicolas, Mortier, Laurent, Atkins, Michael B, Long, Georgina V, Bhatia, Shailender, Lebbé, Celeste, Rutkowski, Piotr, Yokota, Kenji, Yamazaki, Naoya, Kim, Tae M, de Pril, Veerle, Sabater, Javier, Qureshi, Anila, Larkin, James, Ascierto, Paolo A

Volltext

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma von Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D, Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier F, Hill, Andrew, Wagstaff, John, Carlino, Matteo S, Haanen, John B, Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A, Ascierto, Paolo A, Long, Georgina V, Callahan, Margaret K, Postow, Michael A, Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M, Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D

Volltext

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma von Ott, P.A., Pavlick, A.C., Johnson, D.B., Hart, L.L., Infante, J.R., Luke, J.J., Lutzky, J., Rothschild, N., Spitler, L., Cowey, C.L., Alizadeh, A., Salama, A., He, Y., Bagley, R.G., Zhang, J., Hamid, O.

Volltext

LBA68_PR5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma von Larkin, J M G, Chiarion-Sileni, V, Gonzalez, R, Grob, J J, Rutkowski, P, Lao, C, Cowey, C L, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, P F, Smylie, M, Hogg, D, Hill, A, Marquez-Rodas, I, Haanen, J B A G, Rizzo, J, Balogh, A, Hodi, F S, Wolchok, J

Volltext

1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial von Weber, J S, Del Vecchio, M, Mandala, M, Gogas, H, Arance, A M, Dalle, S, Cowey, C L, Schenker, M, Grob, J J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, M O, Maio, M, Middleton, M R, Tang, T, Saci, A, De Pril, V, Lobo, M, Larkin, J M G, Ascierto, P A

Volltext

LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) von Hodi, F S, Chiarion-Sileni, V, Gonzalez, R, Grob, J J, Rutkowski, P, Cowey, C L, Lao, C, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, P F, Smylie, M, Hill, A G, Hogg, D, Marquez-Rodas, I, Jiang, J, Rizzo, J, Larkin, J, Wolchok, J

Volltext

Résultats mis à jour d’un essai de phase III sur le nivolumab associé à l’ipilimumab chez des patients atteints de mélanome avancé (CheckMate 067) von Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.-L., Lao, C.-D., Schadendorf, D., Ferucci, P.-F., Smylie, M., Dummer, R., Hill, A., Haanen, J., Maio, M., McArthur, G., Walker, D., Jiang, J., Horak, C., Larkin, J., Hodi, F.-S.

Volltext

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma von Cowey, C Lance

Volltext

Challenging the standard of care in advanced melanoma: focus on pembrolizumab von Abdul-Karim, Raghad M, Cowey, C Lance

Volltext

REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS von Cowey, CL, Mahnke, L, Espirito, J, Helwig, C, Oksen, D, Bharmal, M

Volltext

PCN50 - Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States von Cowey, CL, Mahnke, L, Espirito, J, Fox, P, Helwig, C, Oksen, D, Bharmal, M

Volltext

Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States von Cowey, CL, Mahnke, L, Espirito, J, Fox, P, Helwig, C, Oksen, D, Bharmal, M

Volltext

Recurrence and survival following preoperative sorafenib for advanced renal cell carcinoma von Rathmell, K., Cowey, C. L., Grigson, G., Watkins, C., Wallen, E., Nielsen, M. E., Pruthi, R., Godley, P. A., Whang, Y. E., Kim, W. Y.

Volltext

Synthesis of lariat ether carboxylic acids based on dibenzo-16-crown-5 von Bartsch, Richard A., Cowey, Charles L., Elshani, Sadik, Goo, Mi-Ja, Huber, Vincent J., Ivy, Sheryl N., Johnson, Russell J., Kim, Jong Seung, Luboch, Elzbieta, Mcdonough, Joseph A., Pugia, Michael J., Son, Byungki, Zhao, Qiang

Volltext

Lariat ether alcohols based on dibenzo-16-crown-5 von Bartsch, Richard A., Bitalac, Leah P., Cowey, Charles L., Elshani, Sadik, Goo, Mi-Ja, Huber, Vincent J., Ivy, Sheryl N., Jang, Youngchan, Johnson, Russell J., Kim, Jong Seung, Luboch, Elzbieta, Mcdonough, Joseph A., Pugia, Michael J., Son, Byungki, Zhao, Qiang

Volltext

Defixio auf Tessera

Volltext bestellen